{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=25&sponsor=AbbVie",
    "query": {
      "sponsor": "AbbVie",
      "page": 25
    },
    "page_size": 10
  },
  "pagination": {
    "page": 25,
    "page_size": 10,
    "total_count": 816,
    "total_pages": 82,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=26&sponsor=AbbVie&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=24&sponsor=AbbVie&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T02:21:32.709Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04274894",
      "title": "A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypogonadism"
      ],
      "interventions": [
        {
          "name": "AndroGel 1.62%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 246,
      "start_date": "2020-05-12",
      "completion_date": "2022-01-07",
      "has_results": true,
      "last_update_posted_date": "2022-12-15",
      "last_synced_at": "2026-10-28T02:21:32.709Z",
      "location_count": 45,
      "location_summary": "Foley, Alabama • Newport Beach, California • Northridge, California + 40 more",
      "locations": [
        {
          "city": "Foley",
          "state": "Alabama"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "San Ramon",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04274894"
    },
    {
      "nct_id": "NCT04445025",
      "title": "Comparison Elagolix vs Depot Leuprolide Prior to Frozen Embryo Transfers in Patients With Endometriosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Infertility",
        "Endometriosis"
      ],
      "interventions": [
        {
          "name": "Elagolix 200 MG",
          "type": "DRUG"
        },
        {
          "name": "Leuprolide Acetate 3.75 MG/ML",
          "type": "DRUG"
        },
        {
          "name": "Lab work",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Colorado Center for Reproductive Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "42 Years",
        "sex": "FEMALE",
        "summary": "21 Years to 42 Years · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2020-09-01",
      "completion_date": "2024-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-02-20",
      "last_synced_at": "2026-10-28T02:21:32.709Z",
      "location_count": 1,
      "location_summary": "Lone Tree, Colorado",
      "locations": [
        {
          "city": "Lone Tree",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04445025"
    },
    {
      "nct_id": "NCT03364725",
      "title": "Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatitis C",
        "Addict Heroin"
      ],
      "interventions": [
        {
          "name": "Glecaprevir-pibrentasvir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Id Care",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "18 Years to 30 Years"
      },
      "enrollment_count": 30,
      "start_date": "2018-01-15",
      "completion_date": "2019-03-01",
      "has_results": false,
      "last_update_posted_date": "2017-12-07",
      "last_synced_at": "2026-10-28T02:21:32.709Z",
      "location_count": 1,
      "location_summary": "Hillsborough, New Jersey",
      "locations": [
        {
          "city": "Hillsborough",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03364725"
    },
    {
      "nct_id": "NCT03695185",
      "title": "A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ulcerative Colitis (UC)"
      ],
      "interventions": [
        {
          "name": "Ravagalimab 600 mg",
          "type": "DRUG"
        },
        {
          "name": "Ravagalimab 300 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 42,
      "start_date": "2019-03-26",
      "completion_date": "2022-01-10",
      "has_results": true,
      "last_update_posted_date": "2023-03-15",
      "last_synced_at": "2026-10-28T02:21:32.709Z",
      "location_count": 12,
      "location_summary": "Tucson, Arizona • Huntington Beach, California • Lakewood, California + 9 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Lakewood",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03695185"
    },
    {
      "nct_id": "NCT03924323",
      "title": "A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Anxiety Disorders,Generalized Anxiety Disorder"
      ],
      "interventions": [
        {
          "name": "Escitalopram",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "7 Years to 17 Years"
      },
      "enrollment_count": 273,
      "start_date": "2019-05-30",
      "completion_date": "2021-09-20",
      "has_results": true,
      "last_update_posted_date": "2022-11-14",
      "last_synced_at": "2026-10-28T02:21:32.709Z",
      "location_count": 39,
      "location_summary": "Dothan, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 35 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Culver City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03924323"
    },
    {
      "nct_id": "NCT06158841",
      "title": "Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Etentamig",
          "type": "DRUG"
        },
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Elotuzumab",
          "type": "DRUG"
        },
        {
          "name": "Selinexor",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 421,
      "start_date": "2024-05-19",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-10-28T02:21:32.709Z",
      "location_count": 46,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 37 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06158841"
    },
    {
      "nct_id": "NCT03926169",
      "title": "A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hidradenitis Suppurativa"
      ],
      "interventions": [
        {
          "name": "Risankizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo for risankizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 243,
      "start_date": "2019-06-03",
      "completion_date": "2021-08-02",
      "has_results": true,
      "last_update_posted_date": "2022-08-11",
      "last_synced_at": "2026-10-28T02:21:32.709Z",
      "location_count": 22,
      "location_summary": "Hot Springs, Arkansas • Bakersfield, California • Los Angeles, California + 17 more",
      "locations": [
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03926169"
    },
    {
      "nct_id": "NCT05283694",
      "title": "A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Dosing in Healthy Male Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "risankizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 48,
      "start_date": "2017-09-11",
      "completion_date": "2018-06-12",
      "has_results": false,
      "last_update_posted_date": "2022-03-17",
      "last_synced_at": "2026-10-28T02:21:32.709Z",
      "location_count": 1,
      "location_summary": "Grayslake, Illinois",
      "locations": [
        {
          "city": "Grayslake",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05283694"
    },
    {
      "nct_id": "NCT02442258",
      "title": "Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Impairment"
      ],
      "interventions": [
        {
          "name": "ABT-493",
          "type": "DRUG"
        },
        {
          "name": "ABT-530",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 46,
      "start_date": "2015-03",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2016-02-22",
      "last_synced_at": "2026-10-28T02:21:32.709Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Orlando, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02442258"
    },
    {
      "nct_id": "NCT05570006",
      "title": "Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "ABBV-668",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2023-03-16",
      "completion_date": "2024-12-23",
      "has_results": true,
      "last_update_posted_date": "2025-12-23",
      "last_synced_at": "2026-10-28T02:21:32.709Z",
      "location_count": 18,
      "location_summary": "Chula Vista, California • Maitland, Florida • Margate, Florida + 13 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Margate",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Macon",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05570006"
    }
  ]
}